CRISPR-Vertex gene editing 1st gets narrow review by FDA panel
A historic moment in pharmaceuticals will happen next week: an FDA advisory committee is set to review the first-ever CRISPR gene editing-based therapy, Vertex Pharmaceuticals and CRISPR Therapeutics’ exa-cel for sickle cell disease (SCD). But what would be even more industry changing would be…
#fda #scd #vertex #crisprtx #african #williamblair #rbccapitalmarkets #adcomm #crisprvertex #crispr